

TYPHIBEV®: Questions and answers

What is TYPHIBEV?

TYPHIBEV is a World Health Organization (WHO)-prequalified typhoid conjugate vaccine (TCV) manufactured by Biological E and developed in collaboration with the GSK Vaccines Institute for Global Health. It contains Vi polysaccharide from *Citrobacter freundii* conjugated to a variant of diphtheria toxin (CRM197) as the carrier protein.

Who can receive TYPHIBEV?

TYPHIBEV can be administered to individuals 6 months to 45 years of age.

What is the dosage schedule for TYPHIBEV?

TYPHIBEV is a one-dose vaccine. A single 0.5 mL dose injected intramuscularly provides long-lasting protection in adults, children, and infants. In countries with a high burden of typhoid or high rates of drug-resistant typhoid, WHO recommends a booster dose, particularly for children who received a first dose younger than 2 years of age.

Is TYPHIBEV safe?

WHO has reviewed clinical data and determined that TYPHIBEV is safe and well-tolerated. Additionally, nearly 150 million children have safely received TCVs in introduction campaigns.

Is TYPHIBEV effective?

Results from a Phase 2/3 study conducted in India demonstrated that the immune response profiles of TYPHIBEV are comparable to Typbar TCV, a WHO-prequalified TCV that has shown 79-85% efficacy against typhoid in Phase 3 clinical trials.

Can TYPHIBEV be given at the same time as other childhood vaccines?

TYPHIBEV can be safely co-administered with yellow fever, measles-rubella, meningococcal conjugate vaccines, polio, and human papillomavirus vaccines.

Is TYPHIBEV prequalified by WHO?

TYPHIBEV was prequalified by WHO in December 2020, indicating it meets international standards for quality, safety, and efficacy and is eligible for procurement by United Nations agencies. It is an important step for inclusion in Gavi, the Vaccine Alliance's investment strategy, which helps finance vaccine access in Gavi-eligible countries.



TYPHIBEV is manufactured by Biological E in Hyderabad, India.

Which countries are using TYPHIBEV?

Nepal, Malawi, Burkina Faso, and Bangladesh introduced TYPHIBEV into their routine immunization programs in 2022, 2023, and 2025, respectively.

(Kenya, Liberia, Niger, Pakistan, Samoa, and Zimbabwe have introduced Typbar TCV,® a comparable TCV product, into their routine immunization programs.)

Does Gavi support the introduction of TYPHIBEV?

Gavi has provided financial support for eligible countries to introduce TCVs since 2018. TYPHIBEV is currently available as an alternative product option with Gavi support.

TYPHOID CONJUGATE VACCINES

What are TCVs?

TCVs are made by linking the Vi capsular polysaccharide of the typhoid or similar bacteria to a more complex protein. Through conjugation, TCVs stimulate parts of the immune system that older typhoid vaccines cannot, thereby inducing a stronger, longer-lasting immunity among a broader age range.

What are the benefits of TCVs?

TCVs offer protection for at least four years with a single dose and are suitable for children 6 months of age and older, allowing delivery through routine childhood immunization programs. Expanded use of TCVs through routine immunization has the potential to reduce the need for antibiotics, slow further emergence of drug-resistant typhoid strains, and save lives. TCVs are projected to be one of the most impactful vaccines for preventing drug-resistance-associated deaths.

Learn more and join the effort at www.takeontyphoid.org.

#TakeOnTyphoid